Company news
Adial Pharmaceuticals, Inc news in 2020
Adial Pharmaceuticals, Inc's news releases, calls and decks from 2020, newest first.
Adial Pharmaceuticals Reaches 35% Enrollment in ONWARD(TM) Pivotal Phase 3 Trial of AD04 for the Treatment of Alcohol Use Disorder
December 16, 2020
Adial Pharmaceuticals Appoints Dr. Jack Reich as Head of Regulatory
December 14, 2020
Adial Pharmaceuticals Schedules Business Update Conference Call to Discuss Planned Acquisition of Purnovate and other Recent Developments
December 9, 2020
Adial Pharmaceuticals Enters Agreement to Acquire Purnovate, a Developer of Potential Therapies for Non-Opioid Pain Reduction and Treatment of Addiction
December 9, 2020
Adial Pharmaceuticals Enters into Common Stock Purchase Agreement with Keystone Capital Partners to Support Strategic Opportunities and Future Growth Initiatives
November 24, 2020
Adial Pharmaceuticals Provides Update on its ONWARD(TM) Pivotal Phase 3 Trial of AD04 for Treatment of Alcohol Use Disorder
November 2, 2020
Adial Pharmaceuticals Announces FDA Reactivation of its Investigational New Drug Application for AD04 in Alcohol Use Disorder
October 20, 2020
Adial Pharmaceuticals Announces Sale of 10,000 COVID-19 Antibody Rapid Test Devices
September 29, 2020
Adial Pharmaceuticals Announces COVID-19 Point-of-Care Antibody Test Granted First Ever FDA Emergency Use Authorization for Use with Fingerstick Blood Samples
September 28, 2020
Adial Pharmaceuticals Files for Expedited Review of AD04 with the FDA
September 24, 2020
Adial Pharmaceuticals and iRemedy Partner to Sell COVID-19 Antibody Test Kits to U.S. Medical Providers and Commence Sales
September 21, 2020
Adial Pharmaceuticals Announces Third-Party Sales and Distribution Agreement with Brik for Rapid Result COVID-19 Antibody Test Kits
August 5, 2020
Adial Pharmaceuticals Schedules Business and Clinical Update Conference Call
July 27, 2020
Adial Pharmaceuticals Receives European Medicines Agency (EMA) Agreement on the Pediatric Investigation Plan (PIP) for AD04 in Alcohol Use Disorder
July 21, 2020
Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Sweden and Estonia
July 5, 2020